PURPOSE: Lung cancer is a biologically diverse disease and relevant models reflecting its diversity would facilitate the improvement of existing therapies. With a view to establishing such models, we developed and evaluated xenografts of a variety of human lung cancers. EXPERIMENTAL DESIGN: Using nonobese diabetic/severe combined immunodeficiency mice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma. After 4 to 12 weeks, xenografts were harvested for serial transplantation and comparison with the original tissue via histologic, chromosomal, and cytogenetic analyses. RESULTS: Xenografts were successfully established. H&E staining showed that xenografts retained major histologic features of the original cancers. Immunohistochemistry and fluorescence in situ hybridization confirmed the human origin of the tumor cells and development in xenografts of murine supportive stroma. Four transplantable lines were developed from rapidly growing tumors (>5 generations), i.e., a small cell lung carcinoma, large cell undifferentiated carcinoma, pulmonary carcinosarcoma, and squamous cell carcinoma. Analyses including spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization, revealed that the xenografts were genetically similar to the original tumors, showing chromosomal abnormalities consistent with karyotypic changes reported for lung cancer. CONCLUSIONS: The subrenal capsule xenograft approach essentially provides a living tumor bank derived from patient material and a means for isolating and expanding specific cell populations. The transplantable tumor lines seem to provide good models for studying various aspects of tumor progression and a platform for developing novel therapeutic regimens, with the possibility of patient-tailored therapies.
PURPOSE:Lung cancer is a biologically diverse disease and relevant models reflecting its diversity would facilitate the improvement of existing therapies. With a view to establishing such models, we developed and evaluated xenografts of a variety of humanlung cancers. EXPERIMENTAL DESIGN: Using nonobese diabetic/severe combined immunodeficiencymice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma. After 4 to 12 weeks, xenografts were harvested for serial transplantation and comparison with the original tissue via histologic, chromosomal, and cytogenetic analyses. RESULTS: Xenografts were successfully established. H&E staining showed that xenografts retained major histologic features of the original cancers. Immunohistochemistry and fluorescence in situ hybridization confirmed the human origin of the tumor cells and development in xenografts of murine supportive stroma. Four transplantable lines were developed from rapidly growing tumors (>5 generations), i.e., a small cell lung carcinoma, large cell undifferentiated carcinoma, pulmonary carcinosarcoma, and squamous cell carcinoma. Analyses including spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization, revealed that the xenografts were genetically similar to the original tumors, showing chromosomal abnormalities consistent with karyotypic changes reported for lung cancer. CONCLUSIONS: The subrenal capsule xenograft approach essentially provides a living tumor bank derived from patient material and a means for isolating and expanding specific cell populations. The transplantable tumor lines seem to provide good models for studying various aspects of tumor progression and a platform for developing novel therapeutic regimens, with the possibility of patient-tailored therapies.
Authors: John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt Journal: Nat Rev Clin Oncol Date: 2012-04-17 Impact factor: 66.675
Authors: Anna V Lapuk; Chunxiao Wu; Alexander W Wyatt; Andrew McPherson; Brian J McConeghy; Sonal Brahmbhatt; Fan Mo; Amina Zoubeidi; Shawn Anderson; Robert H Bell; Anne Haegert; Robert Shukin; Yuzhuo Wang; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Yongjun Zhao; Marco A Marra; Andrea Fanjul; Christopher A Maher; Arul M Chinnaiyan; Mark A Rubin; Himisha Beltran; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins Journal: J Pathol Date: 2012-07 Impact factor: 7.996
Authors: Mariana Varna; Guilhem Bousquet; Irmine Ferreira; Marie Goulard; Morad El-Bouchtaoui; Pierre Mongiat Artus; Jérome Verine; Eric de Kerviler; Lucie Hernandez; Christophe Leboeuf; Bernard Escudier; Luc Legrès; Niclas Setterblad; Hany Soliman; Jean-Paul Feugeas; Anne Janin; Philippe Bertheau Journal: Int J Clin Exp Pathol Date: 2014-05-15
Authors: Mukund Seshadri; Mihai Merzianu; Haikuo Tang; Nestor R Rigual; Maureen Sullivan; Thom R Loree; Saurin R Popat; Elizabeth A Repasky; Bonnie L Hylander Journal: Cancer Biol Ther Date: 2009-12-19 Impact factor: 4.742
Authors: Raelene A VAN Noord; Tina Thomas; Melanie Krook; Sahiti Chukkapalli; Mark J Hoenerhoff; Jonathan R Dillman; Elizabeth R Lawlor; Valerie P Opipari; Erika A Newman Journal: In Vivo Date: 2017 Sep-Oct Impact factor: 2.155
Authors: Junichi Soh; Naoki Okumura; William W Lockwood; Hiromasa Yamamoto; Hisayuki Shigematsu; Wei Zhang; Raj Chari; David S Shames; Ximing Tang; Calum MacAulay; Marileila Varella-Garcia; Tõnu Vooder; Ignacio I Wistuba; Stephen Lam; Rolf Brekken; Shinichi Toyooka; John D Minna; Wan L Lam; Adi F Gazdar Journal: PLoS One Date: 2009-10-14 Impact factor: 3.240